nach oben

Erschienen in:

17.05.2018 | Original Article

Tumor volume as a prognostic marker in p16-positive and p16-negative oropharyngeal cancer patients treated with definitive intensity-modulated radiotherapy

verfasst von: Timo Carpén, MD, Kauko Saarilahti, Caj Haglund, Antti Markkola, Jussi Tarkkanen, Jaana Hagström, Petri Mattila, Antti Mäkitie

Erschienen in: Strahlentherapie und Onkologie | Ausgabe 8/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To investigate the impact of primary gross tumor volume (pGTV) and nodal gross tumor volume (nGTV) in oropharyngeal squamous cell carcinoma (OPSCC) and the difference in their role between human papillomavirus (HPV)-positive and HPV-negative patients.

Methods

The patient cohort consists of 91 OPSCC patients treated with definitive radiochemotherapy or radiotherapy using intensity-modulated radiotherapy (IMRT). All patients had a minimum follow-up of 31 months. Volume measurements were made from computer tomography (CT) scans and HPV status was assessed by p16 immunohistochemistry. The end points were as follows: overall survival (OS), disease-free survival (DFS) and locoregional control (LRC).

Results

pGTV was a significant independent prognostic factor for overall survival (OS; p = 0.020) in p16-negative patients. nGTV of p16-negative tumors had significant prognostic value in all end points in multivariate analyses. High-stage (III–IVc) p16-negative tumors were only associated with significantly poorer OS (p = 0.046) but not with poorer LRC or DFS when compared with the low-stage (I–II) tumors. nGTV of p16-positive tumors was an independent prognostic factor for DFS (p = 0.005) and LRC (p = 0.007) in multivariate analyses.

Conclusion

pGTV may serve as an independent prognostic factor in p16-negative patients and nGTV may serve as an independent prognostic factor both in p16-positive and p16-negative patients treated with radiochemotherapy or radiotherapy using IMRT. Tumor volume may have an impact on selecting patients for de-escalation protocols in the future, both in p16-positive and p16-negative patients.

Chao KS, Ozyigit G, Blanco AI, Thorstad WL, Deasy JO, Haughey BH, Spector GJ, Sessions DG (2004) Intensity-modulated radiation therapy for oropharyngeal carcinoma: impact of tumor volume. Int J Radiat Oncol Biol Phys 59(1):43–50. https://doi.org/10.1016/j.ijrobp.2003.08.004 CrossRefPubMed

Chen SW, Yang SN, Liang JA, Lin FJ, Tsai MH (2009) Prognostic impact of tumor volume in patients with stage III–IVA hypopharyngeal cancer without bulky lymph nodes treated with definitive concurrent chemoradiotherapy. Head Neck 31(6):709–716. https://doi.org/10.1002/hed.21011 CrossRefPubMed

Lok BH, Setton J, Caria N, Romanyshyn J, Wolden SL, Zelefsky MJ, Park J, Rowan N, Sherman EJ, Fury MG, Ho A, Pfister DG, Wong RJ, Shah JP, Kraus DH, Zhang Z, Schupak KD, Gelblum DY, Rao SD, Lee NY (2012) Intensity-modulated radiation therapy in oropharyngeal carcinoma: effect of tumor volume on clinical outcomes. Int J Radiat Oncol Biol Phys 82(5):1851–1857. https://doi.org/10.1016/j.ijrobp.2011.03.029 CrossRefPubMed

He YX, Wang Y, Cao PF, Shen L, Zhao YJ, Zhang ZJ, Chen DM, Yang TB, Huang XQ, Qin Z, Dai YY, Shen LF (2016) Prognostic value and predictive threshold of tumor volume for patients with locally advanced nasopharyngeal carcinoma receiving intensity-modulated radiotherapy. Chin J Cancer 35(1):96. https://doi.org/10.1186/s40880-016-0159-2 CrossRefPubMedPubMedCentral

Linge A, Lohaus F, Lock S, Nowak A, Gudziol V, Valentini C, von Neubeck C, Jutz M, Tinhofer I, Budach V, Sak A, Stuschke M, Balermpas P, Rodel C, Grosu AL, Abdollahi A, Debus J, Ganswindt U, Belka C, Pigorsch S, Combs SE, Monnich D, Zips D, Buchholz F, Aust DE, Baretton GB, Thames HD, Dubrovska A, Alsner J, Overgaard J, Krause M, Baumann M, DKTK-ROG (2016) HPV status, cancer stem cell marker expression, hypoxia gene signatures and tumour volume identify good prognosis subgroups in patients with HNSCC after primary radiochemotherapy: A multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). Radiother Oncol 121(3):364–373. https://doi.org/10.1016/j.radonc.2016.11.008 CrossRefPubMed

Studer G, Lutolf UM, El-Bassiouni M, Rousson V, Glanzmann C (2007) Volumetric staging (VS) is superior to TNM and AJCC staging in predicting outcome of head and neck cancer treated with IMRT. Acta Oncol 46(3):386–394. https://doi.org/10.1080/02841860600815407 CrossRefPubMed

Doweck I, Denys D, Robbins KT (2002) Tumor volume predicts outcome for advanced head and neck cancer treated with targeted chemoradiotherapy. Laryngoscope 112(10):1742–1749. https://doi.org/10.1097/00005537-200210000-00006 CrossRefPubMed

Rutkowski T (2014) The role of tumor volume in radiotherapy of patients with head and neck cancer. Radiat Oncol 9:23. https://doi.org/10.1186/1748-717x-9-23 CrossRefPubMedPubMedCentral

Strongin A, Yovino S, Taylor R, Wolf J, Cullen K, Zimrin A, Strome S, Regine W, Suntharalingam M (2012) Primary tumor volume is an important predictor of clinical outcomes among patients with locally advanced squamous cell cancer of the head and neck treated with definitive chemoradiotherapy. Int J Radiat Oncol Biol Phys 82(5):1823–1830. https://doi.org/10.1016/j.ijrobp.2010.10.053 CrossRefPubMed

10.

Knegjens JL, Hauptmann M, Pameijer FA, Balm AJ, Hoebers FJ, de Bois JA, Kaanders JH, van Herpen CM, Verhoef CG, Wijers OB, Wiggenraad RG, Buter J, Rasch CR (2011) Tumor volume as prognostic factor in chemoradiation for advanced head and neck cancer. Head Neck 33(3):375–382. https://doi.org/10.1002/hed.21459 PubMedCrossRef

11.

Brenner DJ (1993) Dose, volume, and tumor-control predictions in radiotherapy. Int J Radiat Oncol Biol Phys 26(1):171–179CrossRefPubMed

12.

Dubben HH, Thames HD, Beck-Bornholdt HP (1998) Tumor volume: a basic and specific response predictor in radiotherapy. Radiother Oncol 47(2):167–174CrossRefPubMed

13.

Johnson CR, Thames HD, Huang DT, Schmidt-Ullrich RK (1995) The tumor volume and clonogen number relationship: tumor control predictions based upon tumor volume estimates derived from computed tomography. Int J Radiat Oncol Biol Phys 33(2):281–287CrossRefPubMed

14.

Yang SN, Chiou YR, Zhang GG, Chou KT, Huang TC (2017) The clinical outcome correlations between radiation dose and pretreatment metabolic tumor volume for radiotherapy in head and neck cancer: a retrospective analysis. Medicine (Baltimore) 96(26):e7186. https://doi.org/10.1097/MD.0000000000007186 CrossRef

15.

Edge SBBD, Compton CC, Fritz AG, Greene FL, Trotti A (2010) AJCC cancer staging manual, 7th edn. Springer, New York

16.

Edge SB, Compton CC (2010) The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 17(6):1471–1474. https://doi.org/10.1245/s10434-010-0985-4 CrossRefPubMed

17.

Davis KS, Lim CM, Clump DA, Heron DE, Ohr JP, Kim S, Duvvuri U, Johnson JT, Ferris RL (2016) Tumor volume as a predictor of survival in human papillomavirus-positive oropharyngeal cancer. Head Neck 38(Suppl 1):E1613–1617. https://doi.org/10.1002/hed.24287 CrossRefPubMed

18.

Hermans R, Op de beeck K, Van den Bogaert W, Rijnders A, Staelens L, Feron M, Bellon E (2001) The relation of CT-determined tumor parameters and local and regional outcome of tonsillar cancer after definitive radiation treatment. Int J Radiat Oncol Biol Phys 50(1):37–45CrossRefPubMed

19.

Lydiatt WM, Patel SG, O’Sullivan B, Brandwein MS, Ridge JA, Migliacci JC, Loomis AM, Shah JP (2017) Head and Neck cancers-major changes in the American Joint Committee on cancer eighth edition cancer staging manual. CA Cancer J Clin 67(2):122–137. https://doi.org/10.3322/caac.21389 CrossRefPubMed

20.

Amin MB, Edge S, Greene F, Byrd DR, Brookland RK, Washington MK, Gershenwald JE, Compton CC, Hess KR, Sullivan DC, Jessup JM, Brierley JD, Gaspar LE, Schilsky RL, Balch CM, Winchester DP, Asare EA, Madera M, Gress DM, Meyer LR (2017) AJCC cancer staging manual, 8th edn. Springer, New YorkCrossRef

21.

Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tan PF, Westra WH, Chung CH, Jordan RC, Lu C, Kim H, Axelrod R, Silverman CC, Redmond KP, Gillison ML (2010) Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 363(1):24–35. https://doi.org/10.1056/NEJMoa0912217 CrossRefPubMedPubMedCentral

22.

Gillison ML, D’Souza G, Westra W, Sugar E, Xiao W, Begum S, Viscidi R (2008) Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. J Natl Cancer Inst 100(6):407–420. https://doi.org/10.1093/jnci/djn025 CrossRefPubMed

23.

Mehanna H, Beech T, Nicholson T, El-Hariry I, McConkey C, Paleri V, Roberts S (2013) Prevalence of human papillomavirus in oropharyngeal and nonoropharyngeal head and neck cancer—systematic review and meta-analysis of trends by time and region. Head Neck 35(5):747–755. https://doi.org/10.1002/hed.22015 CrossRefPubMed

24.

D’Souza G, Kreimer AR, Viscidi R, Pawlita M, Fakhry C, Koch WM, Westra WH, Gillison ML (2007) Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med 356(19):1944–1956. https://doi.org/10.1056/NEJMoa065497 CrossRefPubMed

25.

Fakhry C, Westra WH, Li S, Cmelak A, Ridge JA, Pinto H, Forastiere A, Gillison ML (2008) Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 100(4):261–269. https://doi.org/10.1093/jnci/djn011 CrossRefPubMed

26.

Bird D, Scarsbrook AF, Sykes J, Ramasamy S, Subesinghe M, Carey B, Wilson DJ, Roberts N, McDermott G, Karakaya E, Bayman E, Sen M, Speight R, Prestwich RJ (2015) Multimodality imaging with CT, MR and FDG-PET for radiotherapy target volume delineation in oropharyngeal squamous cell carcinoma. BMC Cancer 15:844. https://doi.org/10.1186/s12885-015-1867-8 CrossRefPubMedPubMedCentral

27.

Emami B, Sethi A, Petruzzelli GJ (2003) Influence of MRI on target volume delineation and IMRT planning in nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 57(2):481–488. https://doi.org/10.1016/s0360-3016(03)00570-4 CrossRefPubMed

28.

van den Brekel MW, Stel HV, Castelijns JA, Nauta JJ, van der Waal I, Valk J, Meyer CJ, Snow GB (1990) Cervical lymph node metastasis: assessment of radiologic criteria. Radiology 177(2):379–384. https://doi.org/10.1148/radiology.177.2.2217772 CrossRefPubMed

29.

Cantrell SC, Peck BW, Li G, Wei Q, Sturgis EM, Ginsberg LE (2013) Differences in imaging characteristics of HPV-positive and HPV-Negative oropharyngeal cancers: a blinded matched-pair analysis. AJNR Am J Neuroradiol 34(10):2005–2009. https://doi.org/10.3174/ajnr.A3524 CrossRefPubMedPubMedCentral

30.

McIlwain WR, Sood AJ, Nguyen SA, Day TA (2014) Initial symptoms in patients with HPV-positive and HPV-negative oropharyngeal cancer. JAMA Otolaryngol Head Neck Surg 140(5):441–447. https://doi.org/10.1001/jamaoto.2014.141 CrossRefPubMed

31.

Martinez I, Wang J, Hobson KF, Ferris RL, Khan SA (2007) Identification of differentially expressed genes in HPV-positive and HPV-negative oropharyngeal squamous cell carcinomas. Eur J Cancer 43(2):415–432. https://doi.org/10.1016/j.ejca .2006.09.001CrossRefPubMed

32.

Huang SH, O’Sullivan B (2017) Overview of the 8th edition TNM classification for head and neck cancer. Curr Treat Options Oncol 18(7):40. https://doi.org/10.1007/s11864-017-0484-y CrossRefPubMed

33.

van den Broek GB, Rasch CR, Pameijer FA, Peter E, van den Brekel MW, Tan IB, Schornagel JH, de Bois JA, Zijp LJ, Balm AJ (2004) Pretreatment probability model for predicting outcome after intraarterial chemoradiation for advanced head and neck carcinoma. Cancer 101(8):1809–1817. https://doi.org/10.1002/cncr.20556 CrossRefPubMed

Titel: Tumor volume as a prognostic marker in p16-positive and p16-negative oropharyngeal cancer patients treated with definitive intensity-modulated radiotherapy
verfasst von: Timo Carpén, MD
Kauko Saarilahti
Caj Haglund
Antti Markkola
Jussi Tarkkanen
Jaana Hagström
Petri Mattila
Antti Mäkitie
Publikationsdatum: 17.05.2018
Verlag: Springer Berlin Heidelberg
Erschienen in: Strahlentherapie und Onkologie / Ausgabe 8/2018
Print ISSN: 0179-7158
Elektronische ISSN: 1439-099X
DOI: https://doi.org/10.1007/s00066-018-1309-z

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Tumor volume as a prognostic marker in p16-positive and p16-negative oropharyngeal cancer patients treated with definitive intensity-modulated radiotherapy

Abstract

Purpose

Methods

Results

Conclusion

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2018

Inclusion of dosimetric data as covariates in toxicity-related radiogenomic studies

Patterns of care analysis for head & neck cancer of unknown primary site: a survey inside the German society of radiation oncology (DEGRO)

Radiation-induced carotid artery lesions

A feasibility study on adaptive 18F-FDG-PET-guided radiotherapy for recurrent and second primary head and neck cancer in the previously irradiated territory

Keine Verschlechterung der postoperativen Lebensqualität von Ösophaguskarzinompatienten durch neoadjuvante Radiochemotherapie

Keine Überlegenheit der Protonentherapie gegenüber der IMRT beim lokal fortgeschrittenen NSCLC

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie